TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04677712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CCH-aaes
Description: Participants were administered CCH-aaes by subcutaneous injection to both buttocks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression
Description: Participants used a compression garment on both buttocks following subcutaneous CCH-aaes injections.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold Packs
Description: Participants used cold packs applied to the right buttock for 5-10 minutes immediately after subcutaneous CCH-aaes injections.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arnica Gel
Description: Participants used Arnica Gel Patches (Arnica montana 50% and Ledum palustre) immediately after the CCH-aaes injection to the right buttock.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INhance®
Description: Participants used INhance Post-injection Serum topically immediately after the CCH-aaes injection to the right buttock.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PDL
Description: Investigators applied one treatment with PDL to the right buttock between days 1-7 after injection.
Study: NCT04563429

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Vitamin A
Description: Oral administration of 5000 EU of Vitamin A during first 28 days of life
Study: NCT01659645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FACBC
Description: Drug FACBC will be given intravenously (IV) over 2 minutes prior to performing the PET scan
Study: NCT01065688

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en Y reconstruction
Description: surgical procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Billroth-I reconstruction
Description: surgical procedure
Study: NCT02290795

Intervention type: OTHER
Intervention: OCT imaging/HRT imaging
Description: Standard follow up protocol with Optical coherence Tomography (OCT) imaging and Heidelberg Retinal Tomograph (HRT) imaging for glaucoma patients and patients scheduled for Ocriplasmin treatment In case of healthy controls the same investigations will be performed.

Intervention type: OTHER
Intervention: OCT imaging/HRT imaging
Description: Standard follow up protocol with Optical coherence Tomography (OCT) imaging and Heidelberg Retinal Tomograph (HRT) imaging for glaucoma patients and patients scheduled for Ocriplasmin treatment In case of healthy controls the same investigations will be performed.

Intervention type: OTHER
Intervention: OCT imaging/HRT imaging
Description: Standard follow up protocol with Optical coherence Tomography (OCT) imaging and Heidelberg Retinal Tomograph (HRT) imaging for glaucoma patients and patients scheduled for Ocriplasmin treatment In case of healthy controls the same investigations will be performed.

Intervention type: OTHER
Intervention: OCT imaging/HRT imaging
Description: Standard follow up protocol with Optical coherence Tomography (OCT) imaging and Heidelberg Retinal Tomograph (HRT) imaging for glaucoma patients and patients scheduled for Ocriplasmin treatment In case of healthy controls the same investigations will be performed.
Study: NCT03627845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHP-303
Description: Investigational drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT01070160

Intervention type: DRUG
Intervention: Endometrin (progesterone 100mg vaginal inserts)
Description: once a day, 6-8 days as specified (prior to each EMBx)

Intervention type: DRUG
Intervention: Endometrin (progesterone 100mg vaginal inserts)
Description: once a day, 6-8 days as specified (prior to each EMBx)

Intervention type: DRUG
Intervention: Metformin
Description: per clinical care guidelines
Study: NCT02118688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT02113735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.P. Acthar® Gel (repository corticotropin injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.P. Acthar® Gel (repository corticotropin injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.P. Acthar® Gel (repository corticotropin injection)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05459623

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual myofascial release
Description: will receive Manual myofascial release to iliotibial band by having the subject to lie in the side lying position on the unaffected side. The upper leg to be tested was rested on the table with hip and knee flexion. Then the therapist applied a few kilograms of force weight along the iliotibial band course proximally to distally. The therapist will repeat this for 6 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emmett intervention
Description: will receive manual myofascial release and the Emmett intervention with the subject sitting upright on a 45cm wooden chair; light, constant pressure via the middle finger (at a perpendicular angle to the skin) will be applied at both points, three times for 10-20s with 5-10s breaks between. A light sweeping action over the sensory area that will treated will be performed once, using the back of the fingers. The rationale for this is that the light brushing action disperses the sensory awareness to move without being too heavy or specific enough to create muscular response. The sequence performed on one side will then repeated on the opposite leg. In Ross Emmett's teachings of the technique he insists on treatment of both sides when focusing on the lower body (for balance). Once both sides will be completed, the subject will be instructed to walk around the room for a minute.
Study: NCT02988765

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Groin ultrasound +/- fine needle aspiration
Description: Preoperative ultrasound morphometry (USM) of the inguino-femoral lymph nodes (IFLN).~The FNAC and/or FNAB is performed in case of suspicious nodes, if at least one of the selected criteria is relieved during ultrasound
Study: NCT01476657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145 (duvelisib)
Description: Oral Twice A Day (BID) Dosing
Study: NCT00928538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced NFP Care
Description: Usual NFP care plus the enhanced care that includes contraceptive administration and distribution during nurse home visits. Participants will have a choice of combined hormonal contraception (oral, patches or vaginal rings)or progestin-only contraception (oral or depomedroxyprogesterone acetate injections.
Study: NCT04377451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The trial will be conducted in two phases, with a dose escalation of metformin. Metformin dosing will begin at 500mg (children) and 850mg (adults) once daily for 5 days in cohort 1.~Cohort 2 will be received weight-based doses; 5 days of 1000mg (500mg twice daily) for those weighing \<60kg and 5 days of 1500mg (1000mg mane, 500mg nocte) for those weighing ≥60kg
Study: NCT02188030

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Exercise Program
Description: The participants allocated into the GET Group will receive a general exercise training realized in group of workers. Each training session started with a five minute swarm-up by slowly moving the neck, upper back, shoulder, arms and hands through pain-free range of motion; followed by 30 minutes of stretching and strengthening exercises for neck, upper back, shoulder, arms and hands, performed in the standing posture, sitting or lying. For resistance exercise, will be adopted 3 sets of 10 repetitions with a load of 80% of 1 repetitions maximum. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual Exercise Program
Description: The participants allocated into the IET Group will receive a individual and specific strength training with seven different exercises, based in training programme describe by Andersen et al.3 and Sundstrup et al4.~During the intervention period, the training intensity were progressively increased according to the principle of periodization and progressive overload5. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises. Experienced instructors supervised every other training session.
Study: NCT02585011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT02281695

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEP adjusment during the Weaning process
Description: The PEEP will be adjusted after an previously established algorithm and the differences in the arterial blood oxygen partial pressure will be compared.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEP adjusment during the Weaning process
Description: The PEEP will be adjusted after an previously established algorithm and the differences in the arterial blood oxygen partial pressure will be compared.
Study: NCT01356914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-914392
Description: Tablets, Oral, 10 mg, Every Day (QD), 20 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-914392
Description: Tablets, Oral, 10 mg, Three Times Daily (TID), 20 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-914392
Description: Tablets, Oral, 20 mg, Three Times Daily (TID), 20 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, Three Times Daily (TID), 20 days
Study: NCT02796378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Training+Simvastatin+Q10-placebo
Description: 8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10-placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Training+Simvastatin-placebo+Q10-placebo
Description: 8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin-placebo and Q10-placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Training+Simvastatin+Q10
Description: 8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10 400 mg/day.
Study: NCT03534700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: parasacral flap reconstruction
Description: parasacral flap reconstruction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open excision
Description: open excision and healing by secondary intention, marsupialization, excision and primary closure (midline or off-midline), excision and repair by flap.
Study: NCT02387359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plecanatide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plecanatide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT04466800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group_rehabilitation program
Description: Regular physical activity, supervised by a physical education educator, a systematic malnutrition screening and a nutritional follow-up performed by a dietetician.~Patients will follow a 4-week rehabilitation program, comprising 3 physical activity sessions per week for 4 weeks. First sessions will be supervised by a physical activity educator and patients will perform the following sessions at home, using physical training software. The physical activity educator will call patients once a week to ensure the sessions are correctly performed and adapt the program if necessary. Patients will also undergo a nutritional assessment carried out by a dietitian at the beginning of the program. A dietitian will call patients once a week to ensure their nutritional status is appropriate.
Study: NCT01692548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Study: NCT03245450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesilate
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan hydrochloride
Description: IV infusion
Study: NCT00513032

Intervention type: DRUG
Intervention: methylene blue
Description: 5mg.kg-1 methylene blue in 250 ml 5% glucose-saline, administered intravenously approximately 60 min before anaesthesia induction

Intervention type: DRUG
Intervention: methylene blue
Description: 5mg.kg-1 methylene blue in 250 ml 5% glucose-saline, administered intravenously approximately 60 min before anaesthesia induction
Study: NCT01870154

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: The objective of the intervention is learning from the work experience of professionals attending the workshop to know and recognize the risk and process of the burnout syndrome and the characteristics specific to the health setting, as well as promoting prevention lines by transmitting strategies to manage and control the elements and consequences of the syndrome process (physical, psychological, and social).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: The objective of the intervention is learning from the work experience of professionals attending the workshop to know and recognize the risk and process of the burnout syndrome and the characteristics specific to the health setting, as well as promoting prevention lines by transmitting strategies to manage and control the elements and consequences of the syndrome process (physical, psychological, and social).
Study: NCT03283176

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin B12 and Folic Acid
Description: Vitamin B12 and Folic Acid measurement by ELISA technique

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin B12 and Folic Acid
Description: Vitamin B12 and Folic Acid measurement by ELISA technique
Study: NCT02288338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 (Lipitor®)
Description: atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 (Ezetrol®)
Description: After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study: NCT03553823

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsies
Description: At Baseline, two 6-mm punch biopsies were taken, one from the identified active plaque (TCS ≥ 6) and one from never-lesional skin. At the End-of-study Visit, one biopsy was taken from the same area of the active plaque sampled at Baseline.
Study: NCT04769011

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical evaluation
Description: Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule, Social Responsiveness Scale, Children Behavior Check List, Conners' Scale

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation
Description: The participants' motor skills are measured using the Movement Assessment Battery for Children 2 (MABC2) (Henderson et al., 2007), the Developmental Coordination Disorder Questionnaire (DCDQ) (Wilson et al., 2007), and the kinematic analysis of a reach-to-drop task (Forti et al., 2011; Crippa et al., 2015).Sensorimotor domain will be also further investigated with NEPSY-II (Korkman et al., 2007) (Fingertip Tapping, Imitating Hand Positions, Manual Motor Sequences, and Visuomotor Precision).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neurophysiological evaluation
Description: Magnetic Resonance Imaging (structural MRI and DTI)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Genetic evaluation
Description: Either blood or saliva will be obtained for participants for DNA collection. DNA will be extracted in the Molecular Biology Laboratory at the Scientific Institute IRCCS Medea. Captured exome libraries will be sequenced using the Illumina NextSeq 500 in 100 bp paired end reads. Postsequencing reads will be aligned using BWA Enrichment application on BaseSpace. VCF file will be then marked using wANNOVAR (Wang Genomics Lab). The analysis will be focused on non-synonymous variants enrichment in Gene Ontology and Human Phenotype.
Study: NCT01992783

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hi-maize resistant starch
Description: 13.5 g/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 13.5 g/day
Study: NCT02988583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgery using low viscosity silicone oil
Description: Pars plans vitrectomy using low viscosity silicone oil

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery using high viscosity silicone oil
Description: Pars plans vitrectomy using high viscosity silicone oil
Study: NCT02188316

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jumbo forceps
Description: comparison of different polypectomy devices

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hot biopsy forceps
Description: comparison of different polypectomy devices
Study: NCT00705939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa
Description: Intravenous infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa
Description: Intravenous infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa
Description: Intravenous infusion every 2 weeks
Study: NCT01241214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-129968
Description: ACT-129968 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-129968
Description: ACT-129968 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-129968
Description: ACT-129968 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACT-129968
Description: ACT-129968 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-129968
Description: ACT-129968 (Dose 4) \& matching placebo administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACT-129968
Description: ACT-129968 (Dose 4) \& matching placebo administered orally once daily

Intervention type: DRUG
Group type: OTHER
Intervention: Cetirizine
Description: Ceterizine administered once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cetirizine
Description: Ceterizine administered once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered twice daily.
Study: NCT04429620

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunfluorescence
Description: Serum indirect immunofluorescent (IIF) method is used, analysis is performed under an automated microscope.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunfluorescence
Description: Serum indirect immunofluorescent (IIF) method is used, analysis is performed under an automated microscope.
Study: NCT01503255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral group therapy
Description: 6 weekly 90-minute group sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: health education group
Description: 6 weekly 90-minute group sessions
Study: NCT05055193

Intervention type: DRUG
Intervention: Evaluation at 24 months corrected age: respiratory outcome, Neurodevelopmental outcome, Growth outcome
Description: Data concerning the 24 months corrected age outcomes were collected from the medical records of the ECL'AUR preterm infants follow-up network.
Study: NCT02825095

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Talc Pleurodesis
Description: chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indwelling Pleural Catheter
Description: Indwelling Pleural Catheter type PLEURAX will be inserted to the pleural space. the patients will be discharged with the pleural catheter.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chest ultrasound
Description: All insertion of a chest drain will be guided by ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chest ultrasound
Description: All insertion of a chest drain will be guided by ultrasound

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia
Description: Inserting a chest drain will be after local anesthesia with 10-20 mL of Lidocaine hydrochloride 20MG/ML - Esracain injection 2%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia
Description: Inserting a chest drain will be after local anesthesia with 10-20 mL of Lidocaine hydrochloride 20MG/ML - Esracain injection 2%

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest Tube
Description: chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed